{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Anemia&page=20", "query": { "condition": "Chronic Anemia", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 504, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Anemia&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Anemia&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T14:20:45.508Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00593554", "title": "Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Lymphoblastic Leukemia", "Myelodysplasia", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Rabbit ATG", "type": "BIOLOGICAL" }, { "name": "Palifermin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG", "BIOLOGICAL" ], "sponsor": "Sherif S. Farag", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 9, "start_date": "2007-08-07", "completion_date": "2017-07-28", "has_results": true, "last_update_posted_date": "2018-04-10", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00593554" }, { "nct_id": "NCT03329404", "title": "Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Transfusion Dependent Thalassemia" ], "interventions": [ { "name": "Mirasol Red Blood Cells (MIR RBCs)", "type": "DEVICE" }, { "name": "Reference Red Blood Cells (REF RBCs)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Terumo BCTbio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 9, "start_date": "2018-04-12", "completion_date": "2018-12-19", "has_results": true, "last_update_posted_date": "2024-02-14", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 4, "location_summary": "Oakland, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329404" }, { "nct_id": "NCT00224055", "title": "Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Anemia, Iron-Deficiency", "Kidney Failure, Chronic" ], "interventions": [ { "name": "Sodium Ferric Gluconate Complex in Sucrose Injection", "type": "DRUG" }, { "name": "Ferrous sulfate tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Watson Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2003-04", "completion_date": "2004-09", "has_results": true, "last_update_posted_date": "2012-03-29", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 23, "location_summary": "Tucson, Arizona • Los Angeles, California • Palo Alto, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Hines", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00224055" }, { "nct_id": "NCT04657094", "title": "Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autoimmune Hemolytic Anemia", "Chronic Lymphocytic Leukemia", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Warm Antibody Autoimmune Hemolytic Anemia" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2021-03-16", "completion_date": "2027-02-08", "has_results": true, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04657094" }, { "nct_id": "NCT02879305", "title": "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anaemia", "Aspergillosis, Allergic Bronchopulmonary" ], "interventions": [ { "name": "Daprodustat", "type": "DRUG" }, { "name": "rhEPO", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Iron therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2964, "start_date": "2016-09-28", "completion_date": "2020-11-09", "has_results": true, "last_update_posted_date": "2021-12-03", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 126, "location_summary": "Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02879305" }, { "nct_id": "NCT00454246", "title": "A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia" ], "interventions": [ { "name": "methoxy polyethylene glycol-epoetin beta", "type": "DRUG" }, { "name": "epoetin alfa", "type": "DRUG" }, { "name": "darbepoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2007-04", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2011-12-16", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "El Dorado", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00454246" }, { "nct_id": "NCT01736397", "title": "Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Iron Deficiency", "Iron Deficiency Anemia" ], "interventions": [ { "name": "Ferric Citrate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Keryx Biopharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2012-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-10-20", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 20, "location_summary": "Tempe, Arizona • La Mesa, California • Sacramento, California + 17 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "La Mesa", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Edgewater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01736397" }, { "nct_id": "NCT00003961", "title": "Sargramostim After Bone Marrow Transplantation in Treating Patients With Myelodysplastic Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": null, "start_date": "1999-04", "completion_date": "2007-12", "has_results": false, "last_update_posted_date": "2014-04-17", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003961" }, { "nct_id": "NCT01147666", "title": "Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "End Stage Renal Disease", "Anemia" ], "interventions": [ { "name": "Roxadustat", "type": "DRUG" }, { "name": "Epoetin Alfa", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 161, "start_date": "2010-05-17", "completion_date": "2012-10-15", "has_results": true, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 25, "location_summary": "Tempe, Arizona • Pine Bluff, Arkansas • Azusa, California + 22 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Pine Bluff", "state": "Arkansas" }, { "city": "Azusa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147666" }, { "nct_id": "NCT03073369", "title": "Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "CKD", "Chronic Kidney Diseases", "Hepcidin", "Ergocalciferol", "Vitamin D", "Iron-deficiency", "Anemia" ], "interventions": [ { "name": "Ergocalciferol 50000 UNT", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 0, "start_date": "2018-01-01", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2018-03-15", "last_synced_at": "2026-10-24T14:20:45.508Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT03073369" } ] }